Domperidone Updated with New Contraindication for Phaeochromocytoma Patients
Domperidone products now include a contraindication for patients with confirmed or suspected phaeochromocytoma due to severe hypertension risk.
Asset
Domperidone
Indication
Signal assessment
Signal strength
high
Confidence level
high
Why it matters
The new contraindication for domperidone in patients with phaeochromocytoma significantly alters its safety profile, which may lead to reduced prescribing and impact market share. Pharma strategy teams must assess the implications for their portfolios and develop strategies to address potential declines in usage.
Recommended action
Humanexa recommends Investigate.
Analysis
Monitor prescribing trends and any subsequent safety reports related to domperidone in the context of this new contraindication.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.